文献速递口腔修复与种植口腔颌面外科

抗骨吸收或放疗患者种植牙的回顾性临床与影像学数据

Dental Implants in Medically Compromised Patients Undergoing or After Receiving Anti-Resorptive or Radiotherapy: Retrospective Clinical and Radiographic Data.
PubMed 文献 · Clin Oral Implants Res · 2025-09-03

这项回顾性研究评估了接受抗骨吸收治疗(AR)或头颈部放疗(IR)患者中种植牙的临床与影像学结局,共纳入92例患者(IR 59例、AR 32例)的369枚种植体。在平均25个月随访中,IR组种植体存留率为92%、AR组为98%,AR组边缘骨吸收更少;在严格预防措施和综合风险评估下,种植牙可作为这类患者的有效修复选择。

要点

  • IR组种植体存留率92%,AR组98%,AR组结局更优
  • 种植失败风险因素包括新下颌/上颌位点、上颌植入、直径<4.2 mm、吸烟和糖尿病
  • 需严格预防措施:术前2天至术后5天抗生素预防,埋入愈合4个月

核心结论

  • 在综合风险评估和严格预防措施下,种植牙可作为接受或曾接受AR/IR治疗患者的有效修复选择。
  • AR治疗后种植的存留率高于IR治疗后种植,且边缘骨吸收更少。

研究设计与样本

  • 回顾性研究,评估接受或曾接受抗骨吸收治疗(AR)或头颈部放疗(IR)患者中种植牙的临床与影像学结局。
  • 共纳入92例患者(IR 59例、AR 32例),369枚种植体,平均随访25个月(SD:16)。
  • 预防措施包括术前2天至术后5天抗生素预防,以及埋入愈合4个月的一期伤口关闭。

主要发现

  • 随访期间共23枚种植体失败(IR 21枚、AR 2枚),IR组和AR组种植体存留率分别为92%和98%。
  • 种植失败的风险因素包括新下颌/上颌位点、上颌植入、种植体直径<4.2 mm、活跃吸烟和糖尿病。
  • IR组平均边缘骨吸收为0.57 mm(SD:1.51),AR组为-0.09 mm(SD:1.17)。

临床怎么用

  • 对接受或曾接受AR/IR治疗的患者,种植前应进行综合风险评估并严格评估种植适应证。
  • 围手术期应遵循抗生素预防(术前2天至术后5天)和埋入愈合4个月的预防措施。
  • 对存在新下颌/上颌位点、上颌植入、种植体直径<4.2 mm、活跃吸烟或糖尿病等风险因素者需谨慎。

局限性

  • 本研究为回顾性设计,样本量有限(92例患者、369枚种植体),随访时间平均25个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE AND AIM: A retrospective study to evaluate the clinical and radiological outcomes of dental implants placed in compromised patients who have undergone antiresorptive therapy (AR) or head and neck radiotherapy (IR). MATERIAL AND METHODS: Dental implant placement was evaluated in compromised patients undergoing or after receiving AR/IR therapy following specific preventive measures: antibiotic prophylaxis (2 days before and 5 days after surgery) and primary wound closure with submerged healing for 4 months. The primary outcome was implant survival during the observation period. Secondary outcomes included marginal bone loss, occurrence of osteonecrosis, and factors influencing implant survival. RESULTS: A total of 92 patients (59 IR, 32 AR) with 369 dental implants were included in the study. During a mean follow-up period of 25 months (SD: 16), 23 implants were lost (IR: 21, AR: 2). Implant survival rates were 92% and 98% for IR and AR, respectively. Identified risk factors for implant failure included placement in neomandibular/-maxillary sites, maxillary implantation, implant diameter < 4.2 mm, active smoking, and diabetes mellitus. The mean marginal bone loss was 0.57 mm (SD: 1.51) in the IR group and -0.09 mm (SD: 1.17) in the AR group. CONCLUSION: With comprehensive risk assessment and careful evaluation of implant indications, dental implants can serve as an effective dental rehabilitation option for patients undergoing or after receiving AR/IR therapy, provided strict adherence to preventive measures is maintained. Implants placed following AR therapy demonstrate higher survival rates and reduced marginal bone loss compared to those placed after IR therapy.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Mertens C, Staudinger F, Smielowski M, et al. Dental Implants in Medically Compromised Patients Undergoing or After Receiving Anti-Resorptive or Radiotherapy: Retrospective Clinical and Radiographic Data. Clin Oral Implants Res. 2025. PMID: 40899090. doi:10.1111/clr.70040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。